Identification
NameDicloxacillin
Accession NumberDB00485  (APRD00916)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

One of the penicillins which is resistant to penicillinase. [PubChem]

Structure
Thumb
Synonyms
(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Dicloxacilina
Dicloxacillin
Dicloxacillina
Dicloxacilline
Dicloxacillinum
External IDs Bayer 5488 / BRL 1702 / P 1011 / R 13423
Product Ingredients
IngredientUNIICASInChI KeyDetails
Dicloxacillin sodium4CKS6MOL6Z 343-55-5GXOMMGAFBINOJY-SLINCCQESA-MDetails
Dicloxacillin sodium monohydrateNot AvailableNot AvailableNot applicableDetails
Product Images
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dicloxacillin SodiumCapsule500 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-19Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralA S Medication Solutions1990-09-302017-06-20Us
Dicloxacillin SodiumCapsule500 mg/1OralA S Medication Solutions1990-09-302017-06-20Us
Dicloxacillin SodiumCapsule500 mg/1OralA S Medication Solutions1990-09-302017-06-20Us
Dicloxacillin SodiumCapsule250 mg/1OralTeva1990-09-30Not applicableUs00093 3123 01 nlmimage10 eb26f597
Dicloxacillin SodiumCapsule250 mg/1OralA S Medication Solutions1990-09-302017-06-20Us
Dicloxacillin SodiumCapsule250 mg/1OralLiberty Pharmaceuticals, Inc.1990-09-30Not applicableUs
Dicloxacillin SodiumCapsule250 mg/1OralA S Medication Solutions1990-09-302017-06-20Us
Dicloxacillin SodiumCapsule500 mg/1OralRed Pharm Drug, Inc.2011-01-20Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralAvera Mc Kennan Hospital2016-01-28Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralNucare Pharmaceuticals, Inc.1990-09-30Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralPd Rx Pharmaceuticals, Inc.1990-09-30Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralStat Rx USA2011-01-20Not applicableUs
Dicloxacillin SodiumCapsule250 mg/1OralA S Medication Solutions1971-04-012017-06-20Us
Dicloxacillin SodiumCapsule250 mg/1OralPhysicians Total Care, Inc.2004-08-17Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralAv Kare, Inc.2017-03-30Not applicableUs
Dicloxacillin SodiumCapsule250 mg/1OralPd Rx Pharmaceuticals, Inc.1990-09-30Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralTeva1990-09-30Not applicableUs
Dicloxacillin SodiumCapsule250 mg/1OralSandoz1971-04-01Not applicableUs
Dicloxacillin SodiumCapsule250 mg/1OralAvera Mc Kennan Hospital2015-10-01Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralRed Pharm Drug, Inc.1971-04-01Not applicableUs
Dicloxacillin SodiumCapsule250 mg/1OralA S Medication Solutions1990-09-302017-06-20Us
Dicloxacillin SodiumCapsule500 mg/1OralA S Medication Solutions1971-04-01Not applicableUs
Dicloxacillin SodiumCapsule250 mg/1OralRebel Distributors1971-04-01Not applicableUs00781 2248 01 nlmimage10 3245996c
Dicloxacillin SodiumCapsule250 mg/1OralLiberty Pharmaceuticals, Inc.1971-04-01Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralH.J. Harkins Company2011-01-20Not applicableUs00093 3125 01 nlmimage10 dd26eea7
Dicloxacillin SodiumCapsule500 mg/1OralPhysicians Total Care, Inc.1992-10-21Not applicableUs00781 2258 01 nlmimage10 2f3e97b4
Dicloxacillin SodiumCapsule250 mg/1OralAvera Mc Kennan Hospital2016-06-14Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralPd Rx Pharmaceuticals, Inc.1971-04-01Not applicableUs
Dicloxacillin SodiumCapsule250 mg/1OralAidarex Pharmaceuticals LLC1990-09-30Not applicableUs
Dicloxacillin SodiumCapsule250 mg/1OralPd Rx Pharmaceuticals, Inc.1990-09-30Not applicableUs
Dicloxacillin SodiumCapsule500 mg/1OralSandoz1971-04-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AmcidilMacroPhar
BetacloxEskayef
CloxagenGenamerica
DacocilinCCPC
DamacirDamacir
DicillinSandoz
DiclexMeiji
DiclocilBristol-Myers Squibb
DicloplusIcofarma
DiclosonUnison
DicloxalMagma
DicloxgenGeneral Drugs House
DicloxinaECU
DyclobiotMedifarma
DynapenNot Available
PosipenGlaxoSmithKline
QuimocyclarArmofar
StakloxActavis
TerbocloxilTerbol
ZiefmycinYung Shin
Brand mixturesNot Available
Categories
UNIICOF19H7WBK
CAS number3116-76-5
WeightAverage: 470.326
Monoisotopic: 469.026596773
Chemical FormulaC19H17Cl2N3O5S
InChI KeyYFAGHNZHGGCZAX-JKIFEVAISA-N
InChI
InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
IUPAC Name
(2S,5R,6R)-6-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
SMILES
[H][[email protected]]12SC(C)(C)[[email protected]@H](N1C(=O)[[email protected]]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O
Pharmacology
Indication

Used to treat infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.

Structured Indications
Pharmacodynamics

Dicloxacillin is a beta-lactamase resistant penicillin similar to oxacillin. Dicloxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of dicloxacillin results from the inhibition of cell wall synthesis and is mediated through dicloxacillin binding to penicillin binding proteins (PBPs). Dicloxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.

Mechanism of action

Dicloxacillin exerts a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, dicloxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that dicloxacillin interferes with an autolysin inhibitor.

TargetKindPharmacological actionActionsOrganismUniProt ID
Penicillin-binding protein 3Proteinyes
inhibitor
Listeria monocytogenes serotype 4b str. LL195A0A0E1R3H3 details
Penicillin-binding protein 1bProteinyes
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)Q7CRA4 details
Penicillin-binding protein 2aProteinyes
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)Q8DNB6 details
Penicillin-binding protein 3Proteinyes
inhibitor
Streptococcus pneumoniaeQ75Y35 details
Penicillin-binding protein 1AProteinyes
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)Q8DR59 details
Penicillin-binding protein 2BProteinyes
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)P0A3M6 details
Related Articles
Absorption

Absorption of the isoxazolyl penicillins after oral administration is rapid but incomplete: peak blood levels are achieved in 1-1.5 hours. Oral absorption of cloxacillin, dicloxacillin, oxacillin and nafcillin is delayed when the drugs are administered after meals.

Volume of distributionNot Available
Protein binding

Binds to serum protein, mainly albumin.

MetabolismNot Available
Route of elimination

Dicloxacillin sodium is rapidly excreted as unchanged drug in the urine by glomerular filtration and active tubular secretion.

Half life

The elimination half-life for dicloxacillin is about 0.7 hour.

ClearanceNot Available
Toxicity

Oral LD50 in rat is 3579 mg/kg. Symptoms of overexposure include irritation, rash, labored breathing, hives, itching, wheezing, nausea, chills, and fever.

Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcenocoumarolDicloxacillin may decrease the anticoagulant activities of Acenocoumarol.Approved
AclarubicinThe serum concentration of Aclarubicin can be decreased when it is combined with Dicloxacillin.Investigational
AmikacinThe serum concentration of Amikacin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
AmrubicinThe serum concentration of Amrubicin can be decreased when it is combined with Dicloxacillin.Approved, Investigational
annamycinThe serum concentration of annamycin can be decreased when it is combined with Dicloxacillin.Investigational
ApramycinThe serum concentration of Apramycin can be decreased when it is combined with Dicloxacillin.Experimental, Vet Approved
ArbekacinThe serum concentration of Arbekacin can be decreased when it is combined with Dicloxacillin.Approved
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Dicloxacillin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Dicloxacillin.Investigational
ChlortetracyclineThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Chlortetracycline.Approved, Vet Approved
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Dicloxacillin.Approved
DemeclocyclineThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Demeclocycline.Approved
DicoumarolDicloxacillin may decrease the anticoagulant activities of Dicoumarol.Approved
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Dicloxacillin.Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Dicloxacillin.Approved, Investigational
DoxycyclineThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Doxycycline.Approved, Investigational, Vet Approved
EpirubicinThe serum concentration of Epirubicin can be decreased when it is combined with Dicloxacillin.Approved
Ethyl biscoumacetateDicloxacillin may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FluindioneDicloxacillin may decrease the anticoagulant activities of Fluindione.Investigational
FramycetinThe serum concentration of Framycetin can be decreased when it is combined with Dicloxacillin.Approved
GeneticinThe serum concentration of Geneticin can be decreased when it is combined with Dicloxacillin.Experimental
GentamicinThe serum concentration of Gentamicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Dicloxacillin.Experimental
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Dicloxacillin.Approved, Illicit
Hygromycin BThe serum concentration of Hygromycin B can be decreased when it is combined with Dicloxacillin.Vet Approved
IdarubicinThe serum concentration of Idarubicin can be decreased when it is combined with Dicloxacillin.Approved
INNO-206The serum concentration of INNO-206 can be decreased when it is combined with Dicloxacillin.Investigational
KanamycinThe serum concentration of Kanamycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dicloxacillin.Approved
MetrizamideThe serum concentration of Metrizamide can be decreased when it is combined with Dicloxacillin.Approved
MinocyclineThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Minocycline.Approved, Investigational
Mycophenolic acidThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Dicloxacillin resulting in a loss in efficacy.Approved
NeamineThe serum concentration of Neamine can be decreased when it is combined with Dicloxacillin.Experimental
NeomycinThe serum concentration of Neomycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
NetilmicinThe serum concentration of Netilmicin can be decreased when it is combined with Dicloxacillin.Approved
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Dicloxacillin.Approved
OxytetracyclineThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Oxytetracycline.Approved, Vet Approved
ParomomycinThe serum concentration of Paromomycin can be decreased when it is combined with Dicloxacillin.Approved, Investigational
PhenindioneDicloxacillin may decrease the anticoagulant activities of Phenindione.Approved
PhenprocoumonDicloxacillin may decrease the anticoagulant activities of Phenprocoumon.Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dicloxacillin.Approved
PirarubicinThe serum concentration of Pirarubicin can be decreased when it is combined with Dicloxacillin.Investigational
PlicamycinThe serum concentration of Plicamycin can be decreased when it is combined with Dicloxacillin.Approved, Withdrawn
ProbenecidThe serum concentration of Dicloxacillin can be increased when it is combined with Probenecid.Approved
PuromycinThe serum concentration of Puromycin can be decreased when it is combined with Dicloxacillin.Experimental
RibostamycinThe serum concentration of Ribostamycin can be decreased when it is combined with Dicloxacillin.Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Dicloxacillin.Approved
SisomicinThe serum concentration of Sisomicin can be decreased when it is combined with Dicloxacillin.Investigational
SP1049CThe serum concentration of SP1049C can be decreased when it is combined with Dicloxacillin.Investigational
SpectinomycinThe serum concentration of Spectinomycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
StreptomycinThe serum concentration of Streptomycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
StreptozocinThe serum concentration of Streptozocin can be decreased when it is combined with Dicloxacillin.Approved
TetracyclineThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Tetracycline.Approved, Vet Approved
TobramycinThe serum concentration of Tobramycin can be decreased when it is combined with Dicloxacillin.Approved, Investigational
ValrubicinThe serum concentration of Valrubicin can be decreased when it is combined with Dicloxacillin.Approved
WarfarinDicloxacillin may decrease the anticoagulant activities of Warfarin.Approved
ZorubicinThe serum concentration of Zorubicin can be decreased when it is combined with Dicloxacillin.Experimental
Food Interactions
  • Take on an empty stomach, food decreases the availability.
References
Synthesis Reference

Sallmann, A. and Pfister, R.; U.S.Patent 3,558,690; January 26,1971; assigned to Geigy Chemical Corporation. Sallmann, A. and Pfister, R.; US. Patent 3,652,762; March 28,1972; assigned to Ciba Geigy Corporation.

General ReferencesNot Available
External Links
ATC CodesJ01CR50 — Combinations of penicillinsJ01CF01 — Dicloxacillin
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (51.3 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1RecruitingTreatmentHealthy Volunteers1
3CompletedTreatmentBacteremia / Infections, Bacterial / Infections, Gram-Positive Bacterial1
Pharmacoeconomics
Manufacturers
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Wyeth ayerst laboratories
  • Apothecon inc div bristol myers squibb
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg/1
CapsuleOral500 mg/1
Prices
Unit descriptionCostUnit
Dicloxacillin Sodium 500 mg capsule1.25USD capsule
Dicloxacillin 500 mg capsule1.2USD capsule
Dicloxacillin Sodium 250 mg capsule0.69USD capsule
Dicloxacillin 250 mg capsule0.66USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility3.63 mg/LNot Available
logP2.91HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0296 mg/mLALOGPS
logP3.19ALOGPS
logP2.91ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.75ChemAxon
pKa (Strongest Basic)-0.71ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area112.74 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity111.44 m3·mol-1ChemAxon
Polarizability42.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8368
Blood Brain Barrier-0.9903
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.6204
P-glycoprotein inhibitor INon-inhibitor0.8951
P-glycoprotein inhibitor IINon-inhibitor0.9204
Renal organic cation transporterNon-inhibitor0.9629
CYP450 2C9 substrateNon-substrate0.8262
CYP450 2D6 substrateNon-substrate0.905
CYP450 3A4 substrateSubstrate0.5977
CYP450 1A2 substrateInhibitor0.8592
CYP450 2C9 inhibitorNon-inhibitor0.891
CYP450 2D6 inhibitorNon-inhibitor0.918
CYP450 2C19 inhibitorNon-inhibitor0.8832
CYP450 3A4 inhibitorNon-inhibitor0.819
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9186
Ames testNon AMES toxic0.6979
CarcinogenicityCarcinogens 0.5672
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9946 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9996
hERG inhibition (predictor II)Non-inhibitor0.8486
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic acids and derivatives
Sub ClassCarboxylic acids and derivatives
Direct ParentN-acyl-alpha amino acids and derivatives
Alternative ParentsPenams / Dichlorobenzenes / Aryl chlorides / Thiazolidines / Tertiary carboxylic acid amides / Heteroaromatic compounds / Isoxazoles / Azetidines / Thiohemiaminal derivatives / Azacyclic compounds
SubstituentsN-acyl-alpha amino acid or derivatives / Penam / 1,3-dichlorobenzene / Halobenzene / Chlorobenzene / Aryl chloride / Aryl halide / Benzenoid / Monocyclic benzene moiety / Azole
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsdichlorobenzene, penicillin (CHEBI:4511 )

Targets

Kind
Protein
Organism
Listeria monocytogenes serotype 4b str. LL195
Pharmacological action
yes
Actions
inhibitor
General Function:
Not Available
Specific Function:
Penicillin binding
Gene Name:
pbpC
Uniprot ID:
A0A0E1R3H3
Uniprot Name:
Penicillin-binding protein 3
Molecular Weight:
75015.58 Da
References
  1. Gutkind GO, Ogueta SB, de Urtiaga AC, Mollerach ME, de Torres RA: Participation of PBP 3 in the acquisition of dicloxacillin resistance in Listeria monocytogenes. J Antimicrob Chemother. 1990 May;25(5):751-8. [PubMed:2115510 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Transferase activity, transferring acyl groups
Specific Function:
Not Available
Gene Name:
pbp1b
Uniprot ID:
Q7CRA4
Uniprot Name:
Penicillin-binding protein 1b
Molecular Weight:
89479.92 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Transferase activity, transferring acyl groups
Specific Function:
Not Available
Gene Name:
pbp2a
Uniprot ID:
Q8DNB6
Uniprot Name:
Penicillin-binding protein 2a
Molecular Weight:
80797.94 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function:
Not Available
Gene Name:
pbp3
Uniprot ID:
Q75Y35
Uniprot Name:
Penicillin-binding protein 3
Molecular Weight:
45209.84 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Penicillin binding
Specific Function:
Cell wall formation.
Gene Name:
pbpA
Uniprot ID:
Q8DR59
Uniprot Name:
Penicillin-binding protein 1A
Molecular Weight:
79700.9 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Not Available
Specific Function:
Penicillin binding
Gene Name:
penA
Uniprot ID:
P0A3M6
Uniprot Name:
Penicillin-binding protein 2B
Molecular Weight:
73872.305 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, Bachmann K: A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97. doi: 10.1124/dmd.108.020701. Epub 2008 May 27. [PubMed:18505790 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Uniprot Name:
Solute carrier family 15 member 1
Molecular Weight:
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Uniprot Name:
Solute carrier family 15 member 2
Molecular Weight:
81782.77 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297 ]
Drug created on June 13, 2005 07:24 / Updated on September 18, 2017 13:12